Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Net Cash Flow: 2018-2024

Historic Net Cash Flow for Stoke Therapeutics (STOK) over the last 7 years, with Dec 2024 value amounting to -$63.2 million.

  • Stoke Therapeutics' Net Cash Flow rose 58.23% to -$18.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.5 million, marking a year-over-year decrease of 66.34%. This contributed to the annual value of -$63.2 million for FY2024, which is 181.19% down from last year.
  • Stoke Therapeutics' Net Cash Flow amounted to -$63.2 million in FY2024, which was down 181.19% from $77.9 million recorded in FY2023.
  • In the past 5 years, Stoke Therapeutics' Net Cash Flow registered a high of $77.9 million during FY2023, and its lowest value of -$142.0 million during FY2021.
  • Its 3-year average for Net Cash Flow is -$5.6 million, with a median of -$31.3 million in 2022.
  • Its Net Cash Flow has fluctuated over the past 5 years, first tumbled by 319.09% in 2021, then soared by 348.53% in 2023.
  • Over the past 5 years, Stoke Therapeutics' Net Cash Flow (Yearly) stood at $64.8 million in 2020, then slumped by 319.09% to -$142.0 million in 2021, then soared by 77.94% to -$31.3 million in 2022, then spiked by 348.53% to $77.9 million in 2023, then slumped by 181.19% to -$63.2 million in 2024.